|1.||Witzig, Thomas E: 19 articles (07/2013 - 02/2002)|
|2.||Gordon, Leo I: 19 articles (10/2009 - 02/2002)|
|3.||Emmanouilides, Christos: 15 articles (01/2009 - 02/2002)|
|4.||Wiseman, Gregory A: 13 articles (07/2013 - 02/2002)|
|5.||White, Christine A: 12 articles (04/2009 - 02/2002)|
|6.||Molina, Arturo: 12 articles (04/2009 - 06/2004)|
|7.||Schilder, Russell J: 9 articles (09/2007 - 06/2002)|
|8.||Morschhauser, Franck: 7 articles (12/2014 - 07/2007)|
|9.||Grillo-López, Antonio J: 7 articles (02/2005 - 02/2002)|
|10.||Zinzani, Pier Luigi: 6 articles (03/2014 - 07/2007)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
12/01/2014 - "Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life."
01/01/2008 - "Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin's lymphoma."
10/01/2007 - "Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma."
06/01/2013 - "Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma."
10/01/2012 - "Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma."
07/01/2007 - "In this report we describe the efficacy of a combination of (90)Y-Ibritumomab Tiuxetan (Zevalin) and Temozolamide as a maintenance therapy for recurrent PCNS Lymphoma in two patients that are both alive and in complete remission after 9 and 10 months respectively. "
05/15/2004 - "(90)Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with lymphoma. "
02/01/2004 - "This review discusses the clinical trials that have demonstrated the efficacy of ibritumomab tiuxetan and summarizes the safety data in patients with relapsed B-cell non-Hodgkin's lymphomas. "
03/01/2014 - "Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma."
04/01/2008 - "This review will summarize the key trials that led to approval of both (131)I-tositumomab and ibritumomab tiuxetan, discuss recent publications on re-treatment and therapy of de novo indolent lymphoma and aggressive histologies, and conclude with new topics in RIT."
|3.||Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
12/20/2009 - "PURPOSE The randomized First-Line Indolent Trial (FIT) was conducted in patients with advanced follicular lymphoma (FL), to evaluate the safety and efficacy of yttrium-90 ((90)Y) ibritumomab tiuxetan given as consolidation of complete or partial remission. "
06/01/2013 - "Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. "
12/20/2009 - "Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma."
11/10/2008 - "Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma."
12/01/2014 - "The aim of this study was to analyze the outcomes of 37 follicular lymphoma (FL) patients treated with (90)ytrium ibritumomab tiuxetan (90Y-IT), outside of clinical trial, according to protocol ISCRTN36210045, after ≥5 years follow-up to February 2014. "
|4.||B-Cell Lymphoma (Lymphoma, B Cell)
04/01/2011 - "Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab."
08/01/2010 - "Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome."
08/27/2008 - "In the near future many more indications should become apparent and Zevalin should become an important tool in the B-cell lymphoma (low and high grade)."
11/01/2007 - "Several years of development of radioimmunotherapeutic compounds came to fruition in February of 2002 when (90)Y-ibritumomab tiuxetan (Zevalin, Y2B8) was approved in the USA and later in Europe, for the treatment of relapsed or refractory, low grade or transformed B-cell lymphoma. "
01/01/2006 - "Several years of development of radioimmunotherapeutic compounds came to fruition in February of 2002 when 90Y-ibritumomab tiuxetan (Zevalin, Y2B8) was approved in the USA and later in Europe, for the treatment of relapsed or refractory, low grade or transformed B-cell lymphoma in the USA. "
06/01/2006 - "Initial Phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. "
10/01/2004 - "Initial phase I/II trials established the therapeutic dose of ibritumomab tiuxetan for low-grade NHL to be 0.4 mCi/kg, or 0.3 mCi/kg for patients with mild thrombocytopenia. "
12/01/2001 - "A Phase II study of a reduced dose of Zevalin in patients with mild thrombocytopenia demonstrated an ORR of 67% and a 33% CR rate. "
04/01/2003 - "If the degree of BM involvement remains in the 20% to 50% range, re-treatment will involve a similar dose of Zevalin; if it is <20%, patients will receive Zevalin to the maximum allowed cumulative dose of 0.4 mCi/kg (or 0.3 mCi/kg for mild thrombocytopenia). "
06/15/2002 - "The safety and efficacy of radioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32 mCi [1.2 GBq]) was evaluated in 30 patients with mild thrombocytopenia (100-149 x 10(9) platelets/L) who had advanced, relapsed or refractory, low-grade, follicular, or transformed B-cell NHL. "
|1.||ibritumomab tiuxetan (Zevalin)
|4.||Etoposide (VP 16)
|2.||Drug Therapy (Chemotherapy)
|3.||Stem Cell Transplantation
|5.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)